Rare Disease Stocks Drop Over 20% in a Month, Insmed Falls Another 5%

Insmed (INSMED INC: INSM) closed on the Nasdaq at $100.57 on May 28, down 5.48%. Its market capitalization stands at roughly $21.8 billion (about KRW 30 trillion), erasing some $1.1 billion (around KRW 1.5 trillion) in a single day, on trading volume of 1.89 million shares.

In its Q1 results announced May 7, Insmed reported revenue of $306 million and a net loss per share of $0.76. The company reconfirmed its 2026 revenue guidance for Brensupry and Arikayce, yet the stock subsequently endured a mid-teens percentage pullback.

Despite this, leading brokerages including H.C. Wainwright maintain Buy ratings with $200–$230 price targets, highlighting the growth potential of Insmed’s rare respiratory disease portfolio.

Headquartered in Bridgewater, New Jersey, Insmed is a biotech focused on developing treatments for rare and serious diseases. Its core products are Arikayce, for refractory nontuberculous mycobacterial lung disease, and Brensupry, for bronchiectasis. Since its founding in 1988, the company has expanded a clinical pipeline in rare pulmonary and autoimmune disorders. At the recent American Thoracic Society International Conference, Insmed presented multiple new data sets across its respiratory franchise, reinforcing medium- to long-term growth expectations.